(27 days)
No
The 510(k) summary describes a hollow fiber dialyzer, a physical medical device for hemodialysis. There is no mention of software, algorithms, or any technology related to AI or ML. The performance studies focus on physical characteristics and function of the dialyzer.
Yes
The device is a dialyzer used for patients in renal failure requiring hemodialysis, which directly treats a medical condition.
No
The device is a dialyzer used for treating renal failure, not for diagnosing it. Its function is therapeutic, not diagnostic.
No
The device description clearly identifies the device as a "Hollow Fiber Dialyzer," which is a physical medical device used in hemodialysis, not a software-only product. The performance studies also focus on physical characteristics and performance of the dialyzer.
Based on the provided text, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states the device is used for hemodialysis in patients with acute or chronic renal failure. This is a treatment applied directly to the patient's blood, not a test performed on a sample outside the body to diagnose a condition.
- Device Description: The description details a hollow fiber dialyzer, which is a component of a hemodialysis machine used to filter blood.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) to provide diagnostic information. The device's function is therapeutic (filtering blood), not diagnostic.
Therefore, the CLIRANS® E-series Hollow Fiber Dialyzers are a therapeutic device used in the treatment of renal failure, not an IVD.
N/A
Intended Use / Indications for Use
The CLIRANS® E-series Hollow Fiber Dialyzers are indicated for use whenever a patient is found to be in acute or chronic renal failure and hemodialysis is prescribed by a physician. The device should be used only at the direction of a physician who has evaluated all of the pertinent features of the patient's illness. This device is indicated for single use only.
Product codes
KDI
Device Description
The 2.0 m2 CLIRANS® E and EE Series dialyzers that are the subject of this 510(k) are a larger size (larger fiber surface area) of the currently cleared dialyzers (K003425).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following verification tests were performed to demonstrate the substantial equivalence of the larger surface area device to the devices cleared under K003425 and to the Althin AF-220 dialyzers:
- In Vitro Clearance .
- Coefficient of Ultrafiltration, Kuf ●
- In Vitro kuf ●
- Pressure Drop in Blood and Dialysate Compartments .
- Priming Volume ●
- Structural Intregrity (Fiber Leak Test) .
None of the data raises any new issues of safety and effectiveness. Additionally, a risk analysis was conducted and there were no new issues of safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
Page 1/3
NOV 2 0 2001
Terumo Medical Corporation Special 510k - CLIRANS® E-Series Dialyzers Section II. Summary and Certification
K 013550
SECTION II. SUMMARY AND CERTIFICATION
SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION PERTAINING TO SUBSTANTIAL EQUIVALENCE
Device Name A.
CLIRANS® E-Series Dialyzers Proprietary Name Classification Name High Permeability Dialyzer Common Name Hollow Fiber Dialyzer
B. Intended Use
The CLIRANS® E-series Hollow Fiber Dialyzers are indicated for use whenever a patient is found to be in acute or chronic renal failure and hemodialysis is prescribed by a physician. The device should be used only at the direction of a physician who has evaluated all of the pertinent features of the patient's illness. This device is indicated for single use only.
Note: This is the same intended use as the predicate device - CLIRANS® E-Series Hollow Fiber Dialyzer cleared under K003425.
C. Device Description
The 2.0 m2 CLIRANS® E and EE Series dialyzers that are the subject of this 510(k) are a larger size (larger fiber surface area) of the currently cleared dialyzers (K003425).
D. Principle Of Operation / Technology
The 2.0 m2 CLIRANS® E and EE Series dialyzers have the same technological characteristics as the predicate devices.
E. Design / Materials
The 2.0 m2 CLIRANS® E and EE Series dialyzers have the same design and materials as the predicate devices.
1
Terumo Medical Corporation Special 510k - CLIRANS® E-Series Dialyzers Section II. Summary and Certification
613550
F. Specifications
The 2.0 m2 CLIRANS® E and EE Series dialyzers have the same specifications as the predicate devices with the exception that they have a larger number of fibers resulting in an increased surface area.
G. Performance
The following verification tests were performed to demonstrate the substantial equivalence of the larger surface area device to the devices cleared under K003425 and to the Althin AF-220 dialyzers:
- In Vitro Clearance .
- Coefficient of Ultrafiltration, Kuf ●
- In Vitro kuf ●
- Pressure Drop in Blood and Dialysate Compartments .
- Priming Volume ●
- Structural Intregrity (Fiber Leak Test) .
None of the data raises any new issues of safety and effectiveness. Additionally, a risk analysis was conducted and there were no new issues of safety and effectiveness.
Additional Safety Information H.
The CLIRANS® E-Series Dialyzers are classified as Externally Communicating Device, Circulating Blood, Prolonged Contact (24 hrs to 30 days). The device's blood contacting materials were tested in accordance with the tests recommended in the FDA General Program Memorandum #G95-1 (5/1/95): Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices Part-1: Evaluation and Testing". Results of the testing demonstrate that the blood contacting materials are biocompatible.
Sterilization conditions have been validated in accordance with ANSI / AAMI / ISO 11134 Sterilization of Health Care Products - Requirements for Validation and Routine Control - Industrial Moist Heat Sterilization and EN 554 Medical Devices -Method for Routine Validation and Control of Sterilization. The device is sterilized to a SAL of 10°.
2
Substantial Equivalence I.
The CLIRANS® E-Series dialyzers are substantially equivalent in intended use, 1 no OLIC hology/principles of operation, materials and performance to the design, techniology prillialyzers cleared under K003425 and to the Althin AF-220 dialyzers cleared under K992573. Differences between the devices do not raise any significant or new issues of safety or effectiveness.
Submitter Information J.
| Prepared By: | Sandi Hartka
Manager Regulatory Affairs |
|----------------|--------------------------------------------|
| Prepared For: | Terumo Medical Corporation |
| | 125 Blue Ball Road |
| | Elkton, MD 21921 |
| | Phone: (410) 392-7243 |
| | Fax: (410) 398-6079 |
| | Email: sandi.hartka@terumomedical.com |
| Date Prepared: | October 22, 2001 |
3
Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the top half of the circle. Inside the circle is a stylized image of an eagle with three lines representing its wings and a wavy line representing its body.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV 2 0 2001
Ms. Sandi Hartka Manager, Regulatory Affairs Terumo Medical Corporation 125 Blue Ball Road ELKTON MD 21921
Re: K013550
Trade/Device Name: CLIRANS® E Series Hollow Fiber Dialyzers Regulation Number: 21 CFR 876.5860 Regulation Name: High Permeability Hemodialysis System Regulatory Class: Class II Product Code: KDI Dated: October 23, 2001 Received: October 24, 2001
Dear Ms. Hartka:
We have reviewed your Section 510(k) premarket notification of intent to market the device wo nave roviewed your betermined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use surver to May 28, 1976, the enactment date of the Medical Device Amendments, or to conninered prior to May 20, 1978, the excordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The I ou may, dicrorere, mains of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or uny 1 vith all the Act's requirements, including, but not limited to: registration and listing eonly first Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set (21 Or re rate 80); accoming (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
4
:
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 8xx.1xxx | (301) 594-4591 |
|---|---|
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |
Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Nancy Cbrogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
NOV 2 0 2001
510(k) Number (if known): 013550
CLIRANS® E-Series Hollow Fiber Dialyzers Device Name:
Indications For Use:
The CLIRANS® E-series Hollow Fiber Dialyzers are indicated for use whenever The CDHGATIC Is found to be in acute or chronic renal failure and hemodialysis is a pation it 10 lo a physician. The device should be used only at the direction of a problem of a projects This device is indicated for single use only.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use i (Per 21 CFR 801.109) OR
Over-The-Counter Use
(Optional Format 1-2-96)
(Division Sign-Off) J
Division of Reproductive, Abdominal,
and Radiological Devices K013550
510(k) Number